Nivolumab: all 1,113 studies that test it

Page 9 of 12. Open to participants first (176), then studies with results posted, then the rest; newest registration first within each.

• A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational BurdenActive, not recruitingNCT04145115Phase 2
• Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid TumorsStatus unknownNCT04142931Phase 1
• Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04134325Early Phase 1
• Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.Status unknownNCT04134182Phase 2
• PVSRIPO in Combination With Nivolumab in MelanomaWithdrawnNCT04125719Phase 1
• Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal CancerCompletedNCT04124601Phase 2
• Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity StudyCompletedNCT04123925Phase 2
• Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic CancerActive, not recruitingNCT04117087Phase 1
• A Phase 1, Bioavailability Study of Relatlimab in Combination With NivolumabCompletedNCT04112498Phase 1
• Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT04109729Phase 1
• Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell CarcinomaCompletedNCT04107103Phase 2
• STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic AdenocarcinomaCompletedNCT04098432Phase 1/2
• Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II StudyCompletedNCT04095208Phase 2
• Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)CompletedNCT04091490Phase 2
• A Phase 2 Trial for Men With Metastatic Prostatic AdenocarcinomaCompletedNCT04090775Phase 2
• Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation TherapyActive, not recruitingNCT04085250Phase 2
• A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruitingNCT04078295Phase 1/2
• Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm PatientsCompletedNCT04072198Phase 2
• Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLCTerminatedNCT04069936Phase 2
• Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid CancerActive, not recruitingNCT04061980Phase 2
• Nivolumab and Eribulin in HER2 Negative Metastatic Breast CancerStatus unknownNCT04061863Phase 1/2
• CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)WithdrawnNCT04060407Phase 1/2
• SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic CancerCompletedNCT04050085Phase 1
• Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus InfectionWithdrawnNCT04044651Phase 2/3
• Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal CancerTerminatedNCT04044430Phase 1
• A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDSWithdrawnNCT04044209Phase 2
• Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLCActive, not recruitingNCT04043195Phase 1/2
• Nivolumab and Ipilimumab in People With Aggressive Pituitary TumorsCompletedNCT04042753Phase 2
• SBRT as a Vaccination for Metastatic MelanomaWithdrawnNCT04042506Phase 2
• A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid TumorSuspendedNCT04042116Phase 1/2
• Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaCompletedNCT04040231Phase 1
• A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedNCT04039607Phase 3
• A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLCStatus unknownNCT04023617Phase 2
• Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS LymphomaCompletedNCT04022980Phase 1
• Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With MelanomaStatus unknownNCT04021420Phase 1/2
• Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal CancerActive, not recruitingNCT04017650Phase 1/2
• Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung CancerActive, not recruitingNCT04013542Phase 1
• Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.Active, not recruitingNCT04006262Phase 2
• IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBMActive, not recruitingNCT04003649Phase 1
• Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal AdenocarcinomaStatus unknownNCT03995017Phase 1/2
• Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing CystectomyStatus unknownNCT03993249Phase 2
• Neoadjuvant Nivolumab for Operable Esophageal CarcinomaStatus unknownNCT03987815Phase 2
• Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and ChemotherapyWithdrawnNCT03982121Phase 1
• A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete ResectionCompletedNCT03980314Phase 1
• Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic CancerCompletedNCT03970252Early Phase 1
• An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid CancersCompletedNCT03956680Phase 1
• Cryotherapy With in Situ Immunotherapy in Melanoma MetastasisCompletedNCT03949153Phase 1/2
• PAC-1 for Treatment of Refractory, Metastatic Kidney CancerWithdrawnNCT03927248Phase 1/2
• Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade GliomasCompletedNCT03925246Phase 2
• Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer PatientsActive, not recruitingNCT03921684Phase 2
• A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck CancerTerminatedNCT03906526Phase 1
• Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)CompletedNCT03893695Phase 1/2
• Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
• Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent GlioblastomaCompletedNCT03890952Phase 2
• Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingNCT03884998Phase 1
• Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal CancerWithdrawnNCT03879811Phase 2
• A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerStatus unknownNCT03879122Phase 2/3
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActive, not recruitingNCT03873402Phase 3
• iSCORE: Immunotherapy Sequencing in COlon and REctal CancerActive, not recruitingNCT03867799Phase 2
• Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Active, not recruitingNCT03865082Phase 2
• A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung CancerCompletedNCT03850067Phase 1
• Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response PredictionStatus unknownNCT03843515Phase 1
• Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for LymphomaActive, not recruitingNCT03843294Phase 1
• Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular CarcinomaCompletedNCT03841201Phase 2
• Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx CancerCompletedNCT03838263Phase 2
• NADIM II: Neo-Adjuvant ImmunotherapyActive, not recruitingNCT03838159Phase 2
• Nivolumab in Patients With Advanced Cutaneous Squamous Cell CarcinomaStatus unknownNCT03834233Phase 2
• NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerCompletedNCT03832621Phase 2
• Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AMLStatus unknownNCT03825367Phase 1/2
• An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)Status unknownNCT03823625Phase 2
• Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseActive, not recruitingNCT03818685Phase 2
• Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical ResectionTerminatedNCT03812562Early Phase 1
• Testing Immunotherapy Versus Observation in Patients With HPV Throat CancerActive, not recruitingNCT03811015Phase 3
• Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%Status unknownNCT03808480Phase 2
• Nivolumab Based Immunotherapy for Treatment of High Grade Cervical DysplasiaWithdrawnNCT03808168Phase 2
• Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain MetastasesCompletedNCT03807765Phase 1
• Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerActive, not recruitingNCT03803553Phase 3
• Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell LymphomaCompletedNCT03798314Phase 1
• Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid TumorsStatus unknownNCT03792724Phase 1/2
• Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerActive, not recruitingNCT03776487Phase 2
• Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System LymphomaCompletedNCT03770416Phase 2
• An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual DiseaseWithdrawnNCT03770299Phase 2
• VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaActive, not recruitingNCT03769155Phase 1
• Nivolumab With Vismodegib in Patients With Basal Cell Nevus SyndromeWithdrawnNCT03767439Phase 2
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)Active, not recruitingNCT03767348Phase 2
• IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid TumorsCompletedNCT03758781Phase 1
• Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.WithdrawnNCT03758729Phase 2
• Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's LymphomaActive, not recruitingNCT03749018Phase 2
• An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid TumorsCompletedNCT03745807Phase 1
• An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid TumorsCompletedNCT03735628Phase 1
• ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung CancerCompletedNCT03732664Phase 1
• Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid TumorsCompletedNCT03730337Phase 1
• Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaTerminatedNCT03728465Phase 2
• Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine CancerCompletedNCT03728361Phase 2
• Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell TumorsWithdrawnNCT03726281Phase 2
• CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity CancerCompletedNCT03721757Phase 2
• Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal CancerCompletedNCT03712943Phase 1
• Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell LymphomaSuspendedNCT03704714Phase 1/2
• An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaWithdrawnNCT03704077Phase 2

← Nivolumab overview